



## Adjuvant Therapy for Melanoma: Recent and Future Developments

Guest Editor:

**Dr. Satoshi Fukushima**

Department of Dermatology and  
Plastic Surgery, Faculty of Life  
Sciences, Kumamoto University,  
Kumamoto, Japan

Deadline for manuscript  
submissions:

**closed (30 June 2022)**

### Message from the Guest Editor

Adjuvant therapy utilizing immune checkpoint blockades (anti-PD-1 Abs) and targeted therapies (BRAF/MEK inhibitors) against melanoma have been approved several years ago. Now these drugs are widely used in many countries. However, the real-world evidence of adjuvant therapy against melanoma is still lacking. Furthermore, neoadjuvant therapies are now tested its efficacy in many trials.

In this Special Issue: Adjuvant Therapy for Melanoma: Recent and Future Developments, the recent evidence of adjuvant therapy for melanoma will be reviewed. And new original research articles for the future developments of adjuvant therapy are going to be presented. Overall, we are confident that this Special Issue will be of interest to the broad readership of the journal. It will provide substantial information covering our current knowledge and future expectations on adjuvant therapy against melanoma.

Keywords:

- Adjuvant Therapy
- Melanoma
- Immunotherapy
- Targeted therapy
- Neoadjuvant therapy





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. José L. Quiles

Department of Physiology,  
Institute of Nutrition and Food  
Technology “Jose Mataix”,  
Biomedical Research Center,  
University of Granada, Avda.  
Conocimiento s/n, 18100 Armilla,  
Granada, Spain

## Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

## Contact Us

---

*International Journal of Molecular  
Sciences* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/ijms  
ijms@mdpi.com  
X@IJMS\_MDPI